Abstract-Understanding type 2 diabetes is challenged by the diversity of patient phenotypes. Translating data across species and among individuals is a barrier for understanding the genetic loci that underpin this multifactorial disease. Dynamic scaling, based upon dimensional analysis, is a common technique in engineering used to translate data among different systems. The objective of this study was to gain insight using dimensional analysis into the relative changes in insulin production capacity vs. insulin-dependent glucose metabolism in patient groups that represent distinct stages of disease progression. A dimensionless number was derived using variables involved in the production of insulin and in the sensitivity of glucose metabolism to insulin. The resulting dynamic scaling relationship was validated against patient data obtained for over 2000 individuals that range in phenotype from normal to severe type 2 diabetes. Individuals were identified in the third National Health and Nutrition Evaluation Survey. Patient groups clustered in different regions based upon the severity of clinical symptoms. The cross-sectional comparison among patient groups shows that progression from normal to clinical onset of type 2 diabetes exhibits a non-linear change in the ratio of insulin production to insulin-dependent glucose metabolism: normals are balanced, pre-diabetic individuals exhibit an increase, and individuals with clinical type 2 diabetes exhibit a decrease in this ratio. This dimensionless number provides a method for discriminating between patient groups from first principles. By analogy with other dimensionless numbers, this number may be used to monitor basic physiological variables responsible for glucose homeostasis. In addition, a similar dynamic trajectory to the clinical populations could provide a criterion for selecting relevant animal models for diabetes.
INTRODUCTION
Type 2 diabetes is a multifactorial disease embodied by elevated fasting and post-prandial blood glucose; impaired insulin sensitivity in muscle, liver, and adipose tissue; and impaired pancreatic function. 13, 14 The multifactorial nature of type 2 diabetes suggests that individuals, who exhibit similar phenotypes, may harbor multiple pathogenic lesions. Pathogenic lesions manifest themselves as variations in functional responses to common stimuli. Recent technological advances in molecular biology coupled with relevant animal models provide insight into these functional responses that underpin nutrient metabolism and glucose homeostasis within a biological system. 38 However, a significant barrier to progress in understanding this disease is the difficulty in translating data across species and among individuals. 35 In engineering, extrapolating experimental finding among dynamic systems is achieved via dynamic scaling, a technique based upon dimensional analysis. 16 Dimensional analysis is a powerful approach to assess the importance of various components of a dynamic system and to create an expectation of how similar systems should behave. 3 For instance, the Thiele modulus, a dimensionless ratio between rates of reaction and diffusion in porous media, has been used to predict the efficacy of therapeutic antibodies in tumor spheroids. 40 In the cardiovascular area, the Reynolds and Womersley numbers provide a theoretical basis for understanding the physical phenomena associated with hemodynamic flow fields. 41 In vitro model systems, created using similar hemodynamic scales, have been particularly helpful in understanding the biological mechanisms that underpin observed correlations between flow patterns and clinical implications, such as the association between shear stress and atheroslerosis. 31 As illustrated by these examples, providing an expectation of system behavior, in the form of a model, can be particularly valuable in the study of biological systems, where study in vivo may be particularly challenging.
A recent report from the National Research Council identifies a need for deeper integration of theory into biological research. 33 In this context, theory encoded in a computable form (i.e., a mathematical model) facilitates quantitative validation of the theory against data. Mathematical models have long played a prominent role in understanding and mitigating the underlying pathophysiology of type 2 diabetes (e.g., Bergman et al., 5 Kansal, 26 
Klinke 29
). The types of mathematical approaches vary widely and play different roles in improving patient outcomes. However, state-of-the-art approaches for risk assessment and patient stratification in diabetes are largely based upon correlative metrics (e.g., Abdul-Ghani et al., 1 Eddy and Schlessinger, 17, 18 Hanley et al., 24 Ray et al. 37 ). Mechanistic insight into the underlying pathophysiology specific to an individual, even using a simple relationship, may be particularly helpful for assessing risk and identifying biomarkers. The objective of this study was to gain insight into underlying biological phenomena responsible for glucose homeostasis using dimensional analysis. The dimensional analysis provided an index for quantifying the relative changes in insulin production vs. insulin-dependent glucose metabolism in clinical groups that represent different stages of the disease. In addition, this index was derived from measurements typically used in assessing glucose homeostasis in large-scale clinical populations.
MATERIALS AND METHODS

Derivation of a Dimensionless Number
Dimensional analysis was applied following the ''Buckingham P theorem.'' This theorem states that: the functional relationship amonguantities, whose units may be given in terms of u fundamental units, may be written as a function of q À u dimensionless groups (the P's). 7 Six variables were selected to represent important system characteristics of glucose homeostasis. The six variables and their corresponding fundamental units are shown in Table 1 . Five of the six variables are derived from a steady-state mass balance on insulin. Changes in the concentration of insulin (C Ins ) are regulated by the rate of production (i.e., a Á BCM=V) and rate of disposal (i.e., k d Á C Ins ). The sensitivity of glucose metabolism to changes in insulin is characterized by the sixth variable, S Ins . The six variables are comprised of four fundamental units: length, time, mass, and moles. Two dimensionless variables were created from these system variables following from the Buckingham P theorem. Each dimensionless variable was based around one of two core variables, S Ins and BCM. These two variables are thought to be altered in disease. A reduction in insulin sensitivity is thought to occur in patients with type 2 diabetes while a reduction in beta cell mass occurs in patients with type 1 diabetes. Each core variable was combined with the remaining variables. The power associated with each non-core variable was determined such that the product of the core variable and non-core variables gives rise to a dimensionless number. The first dimensionless number based upon S Ins was:
The second dimensionless number based upon BCM was determined to be:
However, values for the variable k d are not typically measured in large-scale clinical trials. The dimensionless numbers were combined to eliminate k d as follows:
Further simplification yields the form of the dimensionless number used in the analysis: 
V
Volume equivalent of the human body length 3 
Clinical Data
The dimensionless number N D was reformulated in terms of variables commonly used in large-scale clinical trials ðÑ D Þ: Values forÑ D were calculated based upon patient-specific data obtained from the third National Health and Nutrition Examination Survey (NHANES III). 11 Conducted from 1988 until 1994 in the United States, the NHANES III reports survey results for over 3600 measured variables in approximately 33,000 individuals. Individuals were filtered from the entire NHANES III cohort based on selfreported fasting greater than 7.5 h and a valid oral glucose tolerance test (OGTT). For our analysis, N D was calculated from the survey results for blood testing, body composition, and OGTTs in adults over 40. The clinical characteristics of the individuals identified in the database range in disease severity from normal to severe diabetic. In addition, each of these individuals were classified into one of three categories based upon the criteria specified by the American Diabetes Association (ADA) for diagnosis of type 2 diabetes (i.e., fasting glucose ‡ 126 mg/dL or plasma glucose following OGTT ‡ 200 mg/dL). 2, 20 The categories were defined as diabetic; pre-diabetic, which included impaired glucose tolerance (IGT) and impaired fasting glucose (IFG); and normals. In addition, individuals identified as exhibiting the clinical symptoms of type 2 diabetes were subdivided into known diabetics (i.e., a health care provider had told them that they have diabetes) and unknown diabetics (i.e., these individuals have not been diagnosed with diabetes). The variables extracted from the NHANES III database that were used in the analysis are highlighted in Table 2 . The entire dataset used in the analysis is found in Table S2 (see supplemental material). Manipulation of the clinical data was performed using R/Bioconductor (see online supplement for sample R script). The two-dimensional probability density function was estimated using kernel density estimation. 21 Kernel density estimation is a non-parametric smoothing technique used to estimate probability density functions from independent samples drawn from the population of interest. While it shares some similarity with estimating a density function using a normalized histogram, the kernel method exhibits less bias in estimating the density function. The bias in a histogram estimator with a bin width h is of order h. In contrast, the kernel is centered at each point and, by using a symmetric kernel, yields a leading bias term for the kernel estimate of order h 2 . Default values for the bandwidth were used. A Student's t-test, with a Welch correction for different degrees of freedom between groups, was used to determine the confidence level associated with the difference between mean values. A p-value less than 0.05 was considered statistically significant.
Classification Methods
As an alternative to ADA criteria, the glucose metabolism and insulin production metrics can be used to classify individuals into severity groups. The accuracy of these metrics for classifying individuals was estimated using an algorithm developed for quantifying significant differences between non-parametric probability density functions. 23 This algorithm considers two non-parametric probability density functions: a function describing the real group, f R (x, y), and a function describing a second group, f M (x, y). One would classify a new observation, x n and y n , as being drawn from the real group if and only if:
where p is the prior probability that an unclassified observation is from the real group. If the relationship shown in Eq. (5) is less than zero, the probability that the observation (x n , y n ) would be misclassified as being from the second group is (1Àp). This criterion can be expressed in terms of a continuous function: The fraction of the real population that can be misclassified as part of the second population (F Mis ) is then:
RESULTS
Derivation of Dimensionless Number
By drawing an analogy to the Reynolds number as being ratio of inertial to viscous forces, I postulated whether a similar relationship could be related to glucose homeostasis. Common wisdom is that type 1 diabetes is related to a loss of insulin production and that type 2 diabetes is related to a loss in insulin-dependent glucose metabolism; therefore, health corresponds to when these ''forces'' are balanced. A dimensionless number was developed from first principles to represent this theory that insulin production and insulindependent glucose metabolism is balanced in health and becomes imbalanced in disease. The dimensionless number, N D , was derived in the following form:
where a is the stimulated insulin production rate per cell, BCM is the beta cell mass, C Ins is the homeostatic concentration of insulin in the body (i.e., fasting plasma insulin), and S Ins is the insulin sensitivity index. The insulin sensitivity index is a measure of the rate of metabolism of glucose as a function of insulin concentration. However, measuring these variables is difficult in practice. As an alternative, the dimensionless number N D was reformulated in terms of quantities that can be readily obtained in large-scale studies. This reformulated relationship, represented by ðÑ D Þ; was developed in the following form:
where SA Ins is the specific activity of insulin, q B is the average density of the human body, Wt is the body weight of an individual, and MW Glc is the molecular weight of glucose. InsResp is the change in insulin concentration in response to an oral glucose tolerance test (OGTT) and is defined as:
where t is the time between blood samples during the OGTT. I1 and I2 are the concentration of insulin in a fasted state (i.e., prior to the OGTT) and following the OGTT, respectively. InsResp represented the insulin production capacity for a population in response to a common stimulus: an OGTT. ''SI Clamp'' is an estimate of the sensitivity of the peripheral tissue to metabolize glucose in response to changes in insulin and is derived from a hyperinsulemic glucose clamp. As insulin resistance plays an important role in the pathogenesis of diabetes, 14,13 the hyperinsulemic clamp sets a high standard for assessing in vivo tissue sensitivity to insulin. 15 Katz et al. 27 define the glucose clamp-derived index of insulin sensitivity as:
where M is the steady state glucose infusion rate (mg/min), G is the steady state blood glucose concentration, dI is the difference between basal and steady state plasma insulin concentration, and Wt is the body weight. However, hyperinsulemic clamps are not easily applied in large-scale investigations due to the invasive nature and complexity of the protocol. Alternative measures have been proposed that are amenable to large-scale investigations and correlate highly with measurements of insulin sensitivity derived from hyperinsulemic clamps (e.g., HOMA 32 and QUICKI 27 ). In this study, QUICKI was used as a surrogate estimate for ''SI Clamp'' (i.e., ''SI Clamp'' % QUICKI). QUICKI was calculated from fasting plasma glucose (G1) and fasting plasma insulin (I1) using the formula reported by Katz et al. 27 :
where G1 is the fasting glucose concentration. The terms in Eq. (9) were classified into two groups: variables that are constant across the patient population and variables that are unique to each individual. Subsequent analysis focused on the ratio of variables that vary across the population. The units associated with the variables in Eq. (9) that are assumed to vary among individuals are defined in Table 2 .
Validation of the Dimensionless Number
Individuals with complete sets of data were identified in the third National Health and Nutrition Examination Survey (NHANES III) 11 and were stratified by disease state: normal (n = 1197), pre-diabetic (n = 512), known diabetic (n = 142), and unknown diabetic (n = 234) (see supplemental Table S1 for patient data). The values for each of the variables reported were combined using Eq. (9) to estimate the dimensionless number,Ñ D ; for each individual. A composite scatter plot for the all of the different patient groups is shown in Fig. 1 . The color intensity shown in Fig. 1 is linearly proportional to the probability density function for observing an individual with similar characteristics. Solid lines, each corresponding to a different patient group, enclose 50% of the population. The diagonal line corresponds to a value of N D equal to one. As the different patient groups clustered in different regions within the plots, the patient populations were also characterized along the diagonal. The diagonal corresponds to the direction that an individual may traverse if they were to increase in weight and maintain all other variables constant, i.e., theŴt direction. However, all of the other variables do vary among individuals. The projection of an individual upon theŴt axis was obtained using a two-dimensional rotation matrix:
where the index i corresponds to the values for a specific individual. In Fig. 2 Fig. 1 . AsÑ D is the ratio of the ordinate to the abscissa shown in Fig. 1 , an increase inÑ D can be achieved by a decrease in the abscissa while maintaining a constant ordinate or by an increase in the ordinate while maintaining a constant abscissa. The density function forÑ D in normals was centered around one while pre-diabetics, on average, exhibited a higher ratio than normals (p < 0.001). Suggesting that in normals there is a balance between insulin production and insulindependent glucose metabolism in individuals with normal glucose measurements. It is interesting to note that the normal group exhibits a slight bias towards lower values forÑ D : In contrast,Ñ D for known diabetics was almost a factor of 10 lower than normals (p < 0.001). Unknown diabetics, as a group, exhibited mixed characteristics between pre-diabetics and known diabetics. Along theŴt axis, the mean value increased as the clinical characteristics changed from normal to pre-diabetic to diabetic. For comparison, values for the homeostasis model assessment (HOMA) were also calculated for each of the patients.
Comparison to Homeostasis Model Assessment
The Homeostasis Model Assessment (HOMA) is used to characterize the relative contributions of insulin resistance (HOMA-IR) and beta cell function (HOMA-B). The HOMA model is an empirical model developed to predict values for these metrics from fasting glucose and insulin measurements. In contrast toÑ D ; this empirical model does not account for differences in plasma volume among individuals. 25 A computer version of this model has been developed but the corresponding equations have not been described in the peer-reviewed literature. 8 As an alternative, simple mathematical equations have been described that approximate the more detailed model. 30 HOMA-IR and HOMA-B can be calculated using the variables present in the NHANES III database from the following relationships:
A composite HOMA scatter plot for the all of the different patient groups is shown in Fig. 3 . The color intensity shown in Fig. 3 is linearly proportional to the probability density function for observing an individual with similar characteristics. Solid lines, each corresponding to a different patient group, enclose 50% of the population.
The HOMA metric provides individual estimates of insulin resistance and beta cell function based upon fasting measurements. In contrast,Ñ D uses both fasting and dynamic measurements to estimate the insulin production capacity and insulin-dependent glucose metabolism. Theoretically, the HOMA andÑ D metrics should provide similar and independent estimates of these important components of glucose homeostasis. Plots of insulin resistance (subplot A) and beta cell function (subplot B) estimated from HOMA andÑ D are shown in Fig. 4 . The denominator ofÑ D (i.e., insulin-dependent glucose metabolism) shows strong positive correlation with HOMA-IR (r = 0.964). This is expected as both metrics are calculated from fasting plasma glucose and fasting plasma insulin values. In contrast, the numerator ofÑ D (i.e., insulin production capacity) and HOMA-B show moderate positive correlation (r = 0.534), as observed previously. 22 However visual inspection of Fig. 4a suggests that the variance in HOMA-B varies with the numerator ofÑ D and raises doubt about the validity of a correlation coefficient. In summary, these results suggest that HOMA-B is not correlated with the increase in plasma insulin following an OGTT.
In Fig. 5 , probability density functions are shown for the different patient groups projected onto the HOMA-B axis (panel A) and the HOMA-IR axis direction (panel B). Note that the marginal distributions for HOMA-B and HOMA-IR are displayed differently compared to the marginal distributions ofÑ D and Wt shown in Fig. 2 . The density function for HOMA-B in normals was similar to pre-diabetic individuals (p = 0.28), while slightly higher from unknown diabetic individuals (p = 0.011). HOMA-B for known diabetic individuals was lower than both normal (p < 0.002) and pre-diabetic (p < 0.001) individuals. However, the known diabetic population appears to exhibit a bimodal distribution. Along the HOMA-IR axis, the mean value increased as the clinical characteristics changed from normal to prediabetic to diabetic (p < 0.001 for each pairwise comparison). In comparison to the dimensionless number results, HOMA metrics do not show that there is an increase in beta cell function in the pre-diabetic state. Moreover, the drop in beta cell function in known diabetic patients, as predicted by HOMA-B, was not as severe as predicted byÑ D : Differences in the two-dimensional probability density functions (PDFs) were used to quantify the ability of these two metrics (i.e., HOMA vs.Ñ D ) to classify individuals into their correct patient groups. For each metric, a p-value of 0.5 was used in Eq. (7) to estimate the fraction of a population that can be misclassified as belonging to another population (see Table 3 ). For 5 out of the 12 possible pairwise comparisons, theÑ D metric performed better than the HOMA metric. The ability of the HOMA metric to classify patient groups correctly is not surprising as the HOMA-B and HOMA-IR metrics are calculated from the same two fasting plasma measurements. Abnormal fasting plasma glucose is one of the measurements that the ADA criteria use to assign an individual to a patient population. In contrast,Ñ D is based upon plasma measurements during a fasting state, OGTT responses, and body weight. Uncorrelated variability in these measurements may increase the likelihood for misclassification.
DISCUSSION
The current methods for clinically classifying patients are based largely upon measurements obtained by sampling from the blood plasma. The limitations 
(a)
Normal; Pre-diabetic; Unknown diabetic; Known diabetic of plasma measurements to estimate beta cell function and insulin action are well documented. 19 Given these limitations, numerous indices have been developed to characterize glucose homeostasis. 12 The disposition index 6 (i.e., the hyperbolic law of glucose tolerance 39 ) bears the most similarity with theÑ D metric and has been defined as the product of the insulin sensitivity index and the insulin response to glucose. P 1 and P 2 represent a dimensionless form of these indices and a dimensionless disposition index would be the product of the P's (i.e., DI ¼ P 1 Á P 2 ). As currently implemented, the indices for insulin sensitivity and insulin response to glucose are dimensional and obtained by fitting the dynamic response in insulin and glucose following an intravenous glucose tolerance test to Bergman's Minimal Model. 4 In contrast toÑ D ; a reduction in either the insulin sensitivity index or insulin response to glucose result in a reduction in the product. Moreover, the disposition index does not consider the size of the system (i.e., the volume of distribution) as a variable. Based upon how dimensionless numbers are used in engineering, the dimensional nature of these indices limits their utility in translating information among systems. From a practical standpoint, understanding the relative influence of ethnic, gender, genetic, and environmental influences on glucose homeostasis is limited in a dimensional context. A dimensionless disposition index would help address some of these influences. However, values for all of the variables required to calculate a dimensionless disposition index are not typically measured in practice. In this paper, a dimensionless number is derived using the available information and validated to provide the foundation for understanding those relative influences.
In contrast to the correlative metrics commonly used in the field, the dimensionless numberÑ D provides a method for distinguishing between different patient phenotypes based upon an understanding of the physiology underlying glucose homeostasis. It was postulated that glucose homeostasis is the net result of a balance between the ability of an individual to produce insulin and an individual's ability to metabolize glucose in response to insulin. Alterations in this balance result in precipitating the clinical symptoms of diabetes. Using this mechanistic basis, the dimensionless numberÑ D facilitates physiological comparisons among individuals through dynamic scaling, 16 i.e., dynamic systems that exhibit a similar value are expected to behave similarly. As shown in Fig. 2 , normals exhibit a value ofÑ D centered around 1. Prediabetics exhibited an increase inÑ D while clinical presentation of diabetes is characterized by a reduction inÑ D : An increase inÑ D corresponds to a decrease in insulin-dependent glucose metabolism relative to what one might expect given an individual's insulin production capacity. A reduction inÑ D is consistent with a reduction in insulin production capacity relative to what one might expect given an individuals body weight and insulin-dependent glucose metabolism. Given a maximum level of insulin production per beta cell, a reduction in insulin production capacity would correspond to a reduction in an individual's beta cell mass. A reduction in beta cell mass has been observed in type 2 diabetics.
10 Recently identified genetic loci that confer increased risk for type 2 diabetes are also associated with beta cell function. 36 It is anticipated thatÑ D can be helpful to rationalize treatment options and identify high-risk sub-populations. This is illustrated by considering individuals with particular characteristics indicated by the numbers superimposed on Fig. 6 . Normal patient groups may not all have the same risk profiles (consider individuals clustered around point 1 vs. point 2 in the panel A in Fig. 6 ). Normal individuals in group 1 exhibit low values forÑ D : A subsequent increase in weight (red arrow), with other metrics remaining constant, for individuals in this subgroup of normals would suggest that they have a higher probability of becoming diabetic. In contrast, normal individuals with higher values forÑ D (point 2) could increase their weight by a similar amount (dotted arrow) and maintain glucose homeostasis. Similarly, consider the trajectories for disease progression for two different pre-diabetic groups (compare individuals around point 3 vs. point 4 in panel B in Fig. 6 ). Patients clustered around point 4 already have a lowÑ D so increases in weight (i.e., traversal in the positiveŴt direction), with other metrics remaining constant, would suggest that they have a higher probability of becoming diabetic. In contrast, a reduction inÑ D would be required for individuals around point 3 to exhibit the same probability for 9 also supports different risk profiles for these patient clusters as individuals with an acute insulin response below the population mean exhibit an increased risk for developing type 2 diabetes. Clinical research inevitably incorporates some level of bias as the patients that are studied have decided to visit a clinician and have agreed to enroll in a study. The NHANES III database provides a glimpse of a population typically unstudied: the unknown diabetic. For whatever reason, a clinician has never told patients in the unknown diabetic group that they have diabetes. In comparison to the known diabetic group, the unknown diabetic population exhibits higher insulin production capacity for the same body weight, is slightly younger (59.7 vs. 60.9 years, p = 0.24), and has lower levels of glycosylated hemaglobin (HbA1c) (6.70 vs. 8.36%, p < 0.0001). The difference in HbA1c suggests that the unknown diabetic group exhibits better long-term control of plasma glucose. Duration of the diabetic symptoms may explain why these groups exhibit different capacities to produce insulin. Individuals classified as unknown diabetics may become known diabetic in time. However, the crosssectional nature of the NHANES study is unable to address that question. Looking forward,Ñ D can be incorporated readily into other large-scale studies as it is calculated from commonly used clinical tests (e.g., an OGTT with plasma insulin measurements). Ultimately, the trends identified using these common clinical tests to estimate insulin-dependent glucose metabolism should be confirmed using more direct test, such as the euglycemic hyperinsulinemic clamp.
In addition, treatment options may be rationalized usingÑ D applied to different diabetic patient groups. Patients with a highÑ D may be successfully managed through weight loss. However, a combination of weight loss and a disease modifying therapy to increasẽ N D may be required for patients with a lowÑ D to revert to a normal phenotype. The dynamic trajectory that patients follows upon treatment (i.e., weight loss alone or in combination with drug treatment) would be important clinical evidence supporting restoration of glucose homeostasis. In engineering, dimensionless numbers provide an important role in analyzing systems that cannot be easily studied at full scale. One might deduce that animal models that exhibit the same dynamic trajectory inÑ D as the clinical population provide the best representation of the human disease. Moreover, realistic models that accurately reflect the disease pathophysiology would be most appropriate for testing new drugs.
Individuals identified in the NHANES III database exclude patients likely to fall within a type 1 diabetes cohort due to constraints on oral glucose tolerance testing (i.e., age greater than 40 and not taking insulin). However, the qualitative analysis afforded byÑ D is relevant for the study of type 1 diabetes. A recent re-analysis of a series of landmark studies suggests that The intensity of the filled color is related to the two-dimensional density of individuals within a category. The x-axis corresponds to the insulindependent glucose metabolism (i.e., C Ins Á S Ins ) and the y-axis corresponds to the insulin production (i.e., a Á BCM).
precipitation of the clinical symptoms of type 1 diabetes is the result of a balance between beta cell mass and body weight. 28 The beta cell mass required to maintain glucose homeostasis is proportional to body weight. In terms of the variables presented here, a reduction in beta cell mass for a constant weight corresponds to traversing in the negativeÑ D direction. As weight increases, the reduction inÑ D necessary for clinical presentation decreases. A similar behavior is observed in the NHANES III data as shown in the panel A in Fig. 6 .
CONCLUSION
Detailed mechanistic models have been created that represent salient features of human physiology relevant to the pathophysiology of diabetes. However, application of such complicated models to provide feedback to individuals is prohibitive. As an alternative, a relationship was created from first principles to provide an expectation of how individuals should behave through dynamic scaling of glucose homeostasis. A reduction in insulin-dependent glucose metabolism and a reduction in insulin production capacity are typically associated with type 2 and type 1 diabetes, respectively. Dimensional analysis demonstrated that insulin-dependent glucose metabolism and insulin production are balanced in normals. Patients with pre-diabetic traits exhibit either a reduced insulin-dependent glucose metabolism or increased insulin production capacity given their body weight. It might be expected that progression to frank diabetes would correspond to further reduction in insulin-dependent glucose metabolism. However, the predominant feature of the population with diabetes was a marked reduction in insulin production capacity. Differences between the expected behaviors and new data provide the engine for scientific progress. 34 The dimensionless relationship developed here may also help improve treatment of diabetes. In particular, this dimensionless number may be used to monitor basic physiological variables responsible for glucose homeostasis in the clinic. Deducing the potential impact ofÑ D from how dimensionless numbers are used in engineering, similarity in dynamic trajectories within this dimensionless ''space'' could provide a criterion for selecting relevant animal models for diabetes. Furthermore, genetic studies could stratify patient populations into different subpopulations based upon their dynamic trajectories. Stratification could improve the power associated with these studies and aid in identifying multivariate contributions. The validation of this dimensionless number is intended to connect the rich history associated with dimensionless numbers in engineering with one of the major health challenges of our time: type 2 diabetes.
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